Last reviewed · How we verify
NCT06788080
Optimization of Biotinylation Protocol for Studies of Red Blood Cell Survival and Function After Transfusion
EARLY_PHASE1 trial testing BioRBC in Measuring Red Blood Cell Survival After Transfusion in 12 participants. Completed in 4 November 2024.
4 November 2024
Quick facts
| Lead sponsor | Vitalant Research Institute |
|---|---|
| Phase | EARLY_PHASE1 |
| Status | Completed |
| Study type | INTERVENTIONAL |
| Allocation | na |
| Design | single group |
| Masking | none |
| Primary purpose | basic science |
| Enrollment | 12 |
| Start date | 7 March 2024 |
| Primary completion | 4 November 2024 |
| Estimated completion | 4 November 2024 |
| Sites | 2 locations across United States |
Drugs / interventions tested
- BioRBC — full drug profile →
Conditions studied
- Measuring Red Blood Cell Survival After Transfusion — all drugs for Measuring Red Blood Cell Survival After Transfusion →
Sponsor
Vitalant Research Institute
Who can join
18 and older, any sex, with Measuring Red Blood Cell Survival After Transfusion. Patients with the condition only — healthy volunteers not accepted.
Sponsor's own description
The goal of this clinical trial is to compare two methods of labeling red blood cells with biotin. The main question to answer is whether red blood cells labeled 48 hours before transfusion survive as long as red blood cells labeled 6 hours before transfusion. Secondary questions are to measure the quality of the red blood cells and whether or not the biotin-labeled red blood cells induce antibodies in transfusion recipients. This study participant will have six study visits: 1. Screening visit, collect 35 ml blood, about 3 tablespoons 2. Donate 500 ml blood 3. Receive 20 ml of biotin labeled blood transfusion, collect 40 ml blood, about 3 tablespoons 4. Return 1 day after transfusion for blood draw (25 ml, about 2 tablespoons) 5. Return 30 days after transfusion for blood draw (25 ml, about 2 tablespoons) 6. Return 90 days after transfusion for blood draw (25 ml, about 2 tablespoons)
Publications & conference data
1 peer-reviewed publication reference this trial (live from Europe PMC):
-
Optimization of biotinylation protocol for next generation studies of red blood cell survival after transfusion.
Kanias T, George G, Sekiya J, Kelly K, et al · · 2025 · cited 4× · PMID 40390385 · DOI 10.1111/trf.18286
Verify or expand the search:
- PubMed search for NCT06788080
- Europe PMC full search
- ASCO Meeting Library
- ESMO Meeting Library
- bioRxiv preprints
- medRxiv preprints
- Google Scholar
Related trials
Other Vitalant Research Institute trials
Trials by the same sponsor.
- NCT01681420 — Improving Blood Safety and HIV Testing in Brazil · NA · completed
Verify against primary sources
- ClinicalTrials.gov — authoritative US registry record
- WHO ICTRP — international registry index
- EU Clinical Trials Register
- Sponsor press releases (Google)
- Trial protocol + status: ClinicalTrials.gov NCT06788080 (US National Library of Medicine, public domain)
- Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
- Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
- Sponsor: as reported to ClinicalTrials.gov by Vitalant Research Institute
- Last refreshed: 22 January 2025
Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT06788080.
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing